Compare IDCC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDCC | BIO |
|---|---|---|
| Founded | 1972 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Laboratory Analytical Instruments |
| Sector | Miscellaneous | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 7.2B |
| IPO Year | 2007 | N/A |
| Metric | IDCC | BIO |
|---|---|---|
| Price | $362.55 | $261.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $412.50 | $358.50 |
| AVG Volume (30 Days) | 219.2K | ★ 296.4K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.80 | N/A |
| Revenue | ★ $307,404,000.00 | N/A |
| Revenue This Year | N/A | $2.51 |
| Revenue Next Year | $3.38 | $3.17 |
| P/E Ratio | $31.22 | ★ $9.72 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $180.60 | $211.43 |
| 52 Week High | $412.60 | $343.12 |
| Indicator | IDCC | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 33.81 |
| Support Level | $350.05 | $251.00 |
| Resistance Level | $382.78 | $264.68 |
| Average True Range (ATR) | 14.85 | 7.45 |
| MACD | -1.63 | -0.12 |
| Stochastic Oscillator | 54.50 | 2.39 |
InterDigital Inc is a research and development company focused on wireless, video, Artificial Intelligence, and related technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, out of which the majority is from China.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.